- Report
- February 2024
- 250 Pages
Global
From €4804EUR$5,000USD£4,131GBP
- Report
- November 2023
- 144 Pages
Global
From €2401EUR$2,499USD£2,065GBP
- Report
- July 2018
- 765 Pages
Global
From €21139EUR$22,000USD£18,177GBP
- Report
- December 2019
- 356 Pages
Global
From €10565EUR$10,995USD£9,084GBP
- Report
- April 2023
- 147 Pages
Global
From €5764EUR$5,999USD£4,956GBP
Lemtrada is a brand name for alemtuzumab, a monoclonal antibody used to treat multiple sclerosis (MS). It is a type of central nervous system (CNS) drug, which are used to treat a variety of neurological conditions. Lemtrada is used to reduce the frequency of relapses in people with relapsing-remitting MS, and to slow the progression of disability. It is administered as an intravenous infusion over two or three days.
The Lemtrada market is made up of pharmaceutical companies that produce and market the drug. These companies are involved in research and development, manufacturing, and marketing of the drug. They also provide support services to healthcare professionals and patients.
Some companies in the Lemtrada market include Sanofi, Bayer, Biogen, Merck, and Novartis. Show Less Read more